Pharmacodynamic study of rapamycin with intermediate- to high-risk localized CaP

[Guest guest]

Given discrepancies between preclinical and clinical observations of mammalian target of rapamycin (mTOR) inhibition in prostate cancer, Duke Medical sought to determine the pharmacodynamic effects of the mTOR/TORC1 inhibitor rapamycin in men with intermediate- to high-risk prostate cancer undergoing radical prostatectomy.... Click

on the below link for the full story:<http://www.urotoday.com/61/browse_categories/prostate_cancer/a_pharmacodynamic_study_of_rapamycin_in_men_with_intermediate_to_highrisk_localized_prostate_cancer__abstract06182010.html>

You're

welcome

to browse within the above medical web site,but you'll be requested

to register, which you can safely do. Non-doctors are welcome and there's never any spam.